Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
| Revenue (TTM) | $11.03B |
| Gross Profit (TTM) | $7.36B |
| EBITDA | $4.18B |
| Operating Margin | 33.60% |
| Return on Equity | 17.40% |
| Return on Assets | 10.50% |
| Revenue/Share (TTM) | $31.07 |
| Book Value | $51.34 |
| Price-to-Book | 7.19 |
| Price-to-Sales (TTM) | 11.91 |
| EV/Revenue | 11.37 |
| EV/EBITDA | 29.55 |
| Quarterly Earnings Growth (YoY) | 26.50% |
| Quarterly Revenue Growth (YoY) | 18.50% |
| Shares Outstanding | $358.28M |
| Float | $351.21M |
| % Insiders | 0.51% |
| % Institutions | 89.58% |
Volatility is currently contracting
Intuitive Surgical's Ion platform is gaining momentum, with rising procedures, a larger installed base and global expansion fueling a second growth engine.
Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.
Robotics is entering a new era as AI fuels humanoid adoption, with four ETFs offering diversified exposure to the sector's growth.
Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.
ISRG's record cash flow is fueling R&D, manufacturing expansion and over 100 da Vinci 5 updates, strengthening its innovation edge.
Intuitive Surgical leads surgical robotics with faster procedure growth and recurring revenue, while Medtronic offers a cheaper, diversified growth profile.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ISRG is expanding in Asia Pacific with a new Penang plant to boost capacity and support rising demand for robotic-assisted surgery.
ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.
ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ISRG and any ticker you trade — then tracks every position and per-strategy win rate.
